Search Results - "Doehner, Hartmut"

Prognostic significance of serum cystatin C in multiple myeloma by Nückel, Holger, Langer, Christian, Herget-Rosenthal, Stefan, Wichert, Marc, Assert, Roland, Döhner, Hartmut, Dührsen, Ulrich, Liebisch, Peter

“…Multiple myeloma (MM) is frequently complicated by renal insufficiency, which is associated with an unfavorable prognosis. Serum cystatin C is a new and…”
Get full text

Acute Myeloid Leukemia by Döhner, Hartmut, Weisdorf, Daniel J, Bloomfield, Clara D

“…Many recent biologic insights have shed light on the nosology of acute myeloid leukemia. Although this new knowledge has not yet had a major influence on the…”
Get full text

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal by Estey, Elihu, Hasserjian, Robert P., Döhner, Hartmut

“…Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with myelodysplastic syndrome (MDS). Although less…”
Get full text

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways by Bullinger, Lars, Döhner, Konstanze, Döhner, Hartmut

“…In recent years, our understanding of the molecular pathogenesis of myeloid neoplasms, including acute myeloid leukemia (AML), has been greatly advanced by…”
Get full text

How I treat refractory and relapsed acute myeloid leukemia by Thol, Felicitas, Döhner, Hartmut, Ganser, Arnold

“…Most patients with acute myeloid leukemia (AML) develop refractory/relapsed (R/R) disease even in the presence of novel and targeted therapies. Given the…”
Get full text

Acute myeloid leukaemia by Estey, Elihu, Döhner, Hartmut

“…Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults. The…”
Get full text

Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications by Marcucci, Guido, Haferlach, Torsten, Döhner, Hartmut

“…Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML) have revealed a striking heterogeneity with regard to the presence of…”
Get full text

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN by Döhner, Hartmut, Wei, Andrew H, Appelbaum, Frederick R, Craddock, Charles, DiNardo, Courtney D, Dombret, Hervé, Ebert, Benjamin L, Fenaux, Pierre, Godley, Lucy A, Hasserjian, Robert P, Larson, Richard A, Levine, Ross L, Miyazaki, Yasushi, Niederwieser, Dietger, Ossenkoppele, Gert, Röllig, Christoph, Sierra, Jorge, Stein, Eytan M, Tallman, Martin S, Tien, Hwei-Fang, Wang, Jianxiang, Wierzbowska, Agnieszka, Löwenberg, Bob

“…The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely…”
Get full text

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia by Tausch, Eugen, Close, William, Dolnik, Anna, Bloehdorn, Johannes, Chyla, Brenda, Bullinger, Lars, Döhner, Hartmut, Mertens, Daniel, Stilgenbauer, Stephan

Get full text

From pathogenesis to treatment of chronic lymphocytic leukaemia by Stilgenbauer, Stephan, Zenz, Thorsten, Mertens, Daniel, Küppers, Ralf, Döhner, Hartmut

“…Key Points Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. It is characterized by the accumulation of small B…”
Get full text

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL by Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Döhner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F., Kipps, Thomas J.

“…The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad…”
Get full text

Circulating microRNAs in hematological diseases: principles, challenges, and perspectives by Grasedieck, Sarah, Sorrentino, Antonio, Langer, Christian, Buske, Christian, Döhner, Hartmut, Mertens, Daniel, Kuchenbauer, Florian

“…The complex microRNA (miRNA) network plays an important role in the regulation of cellular processes such as development, differentiation, and apoptosis…”
Get full text

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial by Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna Maria, Goede, Valentin, Herling, Carmen Diana, Cramer, Paula, Langerbeins, Petra, von Tresckow, Julia, Engelke, Anja, Maurer, Christian, Kovacs, Gabor, Herling, Marco, Tausch, Eugen, Kreuzer, Karl-Anton, Eichhorst, Barbara, Böttcher, Sebastian, Seymour, John F., Ghia, Paolo, Marlton, Paula, Kneba, Michael, Wendtner, Clemens-Martin, Döhner, Hartmut, Stilgenbauer, Stephan, Hallek, Michael

“…Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for…”
Get full text

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel by Döhner, Hartmut, Estey, Elihu, Grimwade, David, Amadori, Sergio, Appelbaum, Frederick R., Büchner, Thomas, Dombret, Hervé, Ebert, Benjamin L., Fenaux, Pierre, Larson, Richard A., Levine, Ross L., Lo-Coco, Francesco, Naoe, Tomoki, Niederwieser, Dietger, Ossenkoppele, Gert J., Sanz, Miguel, Sierra, Jorge, Tallman, Martin S., Tien, Hwei-Fang, Wei, Andrew H., Löwenberg, Bob, Bloomfield, Clara D.

“…The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010,…”
Get full text

Genomic Classification and Prognosis in Acute Myeloid Leukemia by Papaemmanuil, Elli, Gerstung, Moritz, Bullinger, Lars, Gaidzik, Verena I, Paschka, Peter, Roberts, Nicola D, Potter, Nicola E, Heuser, Michael, Thol, Felicitas, Bolli, Niccolo, Gundem, Gunes, Van Loo, Peter, Martincorena, Inigo, Ganly, Peter, Mudie, Laura, McLaren, Stuart, O’Meara, Sarah, Raine, Keiran, Jones, David R, Teague, Jon W, Butler, Adam P, Greaves, Mel F, Ganser, Arnold, Döhner, Konstanze, Schlenk, Richard F, Döhner, Hartmut, Campbell, Peter J

“…The authors identify 11 discrete genetic subsets of acute myeloid leukemia on the basis of the expression and coexpression of particular mutations. Prospective…”
Get full text

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts by Dombret, Hervé, Seymour, John F., Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Noppeney, Richard, Stone, Richard M., Minden, Mark D., McIntyre, Heidi, Songer, Steve, Lucy, Lela M., Beach, C.L., Döhner, Hartmut

“…This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age ≥65…”
Get full text

Mutations driving CLL and their evolution in progression and relapse by Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N., Stewart, Chip, Reiter, Johannes G., Bahlo, Jasmin, Kluth, Sandra, Bozic, Ivana, Lawrence, Mike, Böttcher, Sebastian, Carter, Scott L., Cibulskis, Kristian, Mertens, Daniel, Sougnez, Carrie L., Rosenberg, Mara, Hess, Julian M., Edelmann, Jennifer, Kless, Sabrina, Kneba, Michael, Ritgen, Matthias, Fink, Anna, Fischer, Kirsten, Gabriel, Stacey, Lander, Eric S., Nowak, Martin A., Döhner, Hartmut, Hallek, Michael, Neuberg, Donna, Getz, Gad, Stilgenbauer, Stephan, Wu, Catherine J.

“…Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and therapy are central questions in cancer biology. Here we…”
Get full text

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet by Sanz, Miguel A., Fenaux, Pierre, Tallman, Martin S., Estey, Elihu H., Löwenberg, Bob, Naoe, Tomoki, Lengfelder, Eva, Döhner, Hartmut, Burnett, Alan K., Chen, Sai-Juan, Mathews, Vikram, Iland, Harry, Rego, Eduardo, Kantarjian, Hagop, Adès, Lionel, Avvisati, Giuseppe, Montesinos, Pau, Platzbecker, Uwe, Ravandi, Farhad, Russell, Nigel H., Lo-Coco, Francesco

“…Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important…”
Get full text

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial by DiNardo, Courtney D, Schuh, Andre C, Stein, Eytan M, Montesinos, Pau, Wei, Andrew H, de Botton, Stéphane, Zeidan, Amer M, Fathi, Amir T, Kantarjian, Hagop M, Bennett, John M, Frattini, Mark G, Martin-Regueira, Patricia, Lersch, Frederik, Gong, Jing, Hasan, Maroof, Vyas, Paresh, Döhner, Hartmut

“…Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine…”
Get full text

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine by Pratz, Keith W, Jonas, Brian A, Pullarkat, Vinod, Recher, Christian, Schuh, Andre C, Thirman, Michael J, Garcia, Jacqueline S, DiNardo, Courtney D, Vorobyev, Vladimir, Fracchiolla, Nicola S, Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, Döhner, Hartmut

“…There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with…”
Get full text